Resources
Changing the Fate of Patients with Chronic Limb-Threatening Ischemia: The Renaissance of Venous Arterialization
In this presentation, Dr. Miguel Montero discusses his innovative work in venous arterialization as a treatment option for patients with chronic limb-threatening ischemia. He discusses changes in demographics of these patients, trends and limits of modern vascular care, and alternative care options.
This Michael E. DeBakey Department of Surgery Grand Rounds session took place on Wednesday, February 10, 2021 at 7:00 A.M..
CME Information
CME Credit Available
You may claim CME credit after watching this activity.
You will be redirected to an outside site when claiming credit and may be asked to register or log in.
Needs Statement
General, plastic, thoracic, vascular, cardiothoracic, abdominal transplantation and surgical oncology physicians, residents, fellows and medical students need to be regularly updated on novel therapies, as well as advances in surgical care and clinical practices that will aid them in treating a variety of surgical procedures to increase the patient care experience and improve practice efficiency.
Objectives
At the conclusion of the session, the participants should be able to:
- Describe the contemporary state of peripheral artery disease (PAD).
- Discuss how to identify a no option (or poor option) scenario of PAD with chronic limb-threatening ischemia.
- Review the role of arterialization in contemporary limb salvage.
Target Audience
- Physicians
- Medical Students
- Fellows
- Residents
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Program Director
-
James W. Suliburk, M.D., FACS
Associate Professor and Chief, Endocrine Surgery
Baylor College of Medicine
Term of Approval
February 1, 2021 through February 28, 2023. Original release date: February 1, 2021.
Disclosure Policy
The Office of Continuing Medical Education (OCME) makes every effort to develop CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial SupportSM, Baylor College of Medicine (BCM) has implemented a mechanism requiring everyone in a position to control the content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.
Baylor College of Medicine does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.
If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the questions about balance in the CME activity evaluation candidly.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Miguel Montero, M.D.
Associate Professor of Surgery
Baylor College of Medicine
Disclosure:
- Consultancy: Bard; Boston Scientific; Cook; Limflow; Veryan
- Ownership Interests (stock, stock options, excluding diversified mutual funds): Profuse; Thermopeutics
Program Director
-
James W. Suliburk, M.D., FACS
Associate Professor and Chief, Endocrine Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
Michele Loor, M.D., FACS
Assistant Professor of Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Todd Rosengart, M.D., F.A.C.S.
DeBakey-Bard Chair of Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
James W. Suliburk, M.D., FACS
Associate Professor and Chief, Endocrine Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Contributor
-
Miguel Montero, M.D.
Associate Professor of Surgery
Baylor College of Medicine
Disclosure:
- Consultancy: Bard; Boston Scientific; Cook; Limflow; Veryan
- Ownership Interests (stock, stock options, excluding diversified mutual funds): Profuse; Thermopeutics
CME Credit Available
You may claim CME credit after watching this activity.
You will be redirected to an outside site when claiming credit and may be asked to register or log in.